Camus Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.60 M
as on 13-12-2024
- Paid Up Capital ₹ 2.50 M
as on 13-12-2024
- Company Age 27 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.35 Cr
as on 13-12-2024
- Satisfied Charges ₹ 9.17 Cr
as on 13-12-2024
- Revenue 170.66%
(FY 2023)
- Profit 172.00%
(FY 2023)
- Ebitda 234.28%
(FY 2023)
- Net Worth 7.58%
(FY 2023)
- Total Assets 26.34%
(FY 2023)
About Camus Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.60 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹9.35 Cr. The company has closed loans amounting to ₹9.17 Cr, as per Ministry of Corporate Affairs (MCA) records.
Suresh Dhabash and Dinesh Kumar serve as directors at the Company.
- CIN/LLPIN
U24232RJ1997PTC013970
- Company No.
013970
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jul 1997
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Camus Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Dhabash  | Director | 20-Sep-2018 | Current |
| Dinesh Kumar | Director | 20-Sep-2018 | Current |
Financial Performance of Camus Pharma.
Camus Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 170.66% increase. The company also saw a substantial improvement in profitability, with a 172% increase in profit. The company's net worth moved up by a moderate rise of 7.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Camus Pharma?
In 2023, Camus Pharma had a promoter holding of 100.00%. The company had 4 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Camus Builders Private LimitedActive 17 years 4 monthsSuresh Dhabash and Dinesh Kumar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 24 Jun 2024 | ₹1.50 Cr | Open |
Others Creation Date: 19 Nov 2022 | ₹7.85 Cr | Open |
Others Creation Date: 04 May 2018 | ₹1.50 M | Satisfied |
How Many Employees Work at Camus Pharma?
Unlock and access historical data on people associated with Camus Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Camus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Camus Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
